Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

HOWL

Werewolf Therapeutics (HOWL)

Werewolf Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:HOWL
DateTimeSourceHeadlineSymbolCompany
11/20/20247:00AMGlobeNewswire Inc.Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
11/07/20248:09AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOWLWerewolf Therapeutics Inc
11/07/20248:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
11/07/20248:02AMGlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
11/07/20248:00AMGlobeNewswire Inc.Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
10/31/20247:00AMGlobeNewswire Inc.Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory DiseasesNASDAQ:HOWLWerewolf Therapeutics Inc
10/04/20248:00AMGlobeNewswire Inc.Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
09/03/20247:00AMGlobeNewswire Inc.Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/20246:21AMEdgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/20246:12AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOWLWerewolf Therapeutics Inc
08/08/20246:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/20246:05AMGlobeNewswire Inc.Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
06/25/20246:00AMGlobeNewswire Inc.Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaNASDAQ:HOWLWerewolf Therapeutics Inc
06/03/20246:56AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
06/01/20248:00AMGlobeNewswire Inc.Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid TumorsNASDAQ:HOWLWerewolf Therapeutics Inc
05/30/20247:00AMGlobeNewswire Inc.Werewolf Therapeutics to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
05/28/20243:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
05/24/20246:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
05/24/20246:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
05/24/20246:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
05/24/20246:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
05/23/20244:00PMGlobeNewswire Inc.Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
05/03/20246:00AMGlobeNewswire Inc.Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
04/24/20249:05AMGlobeNewswire Inc.Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
04/23/20247:00AMGlobeNewswire Inc.Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
04/05/20243:30PMGlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
04/04/20243:30PMGlobeNewswire Inc.Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
03/07/20246:22AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOWLWerewolf Therapeutics Inc
03/07/20246:15AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HOWLWerewolf Therapeutics Inc
03/07/20246:11AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HOWL

Your Recent History

Delayed Upgrade Clock